Lineage Cell Therapeutics Inc Stock

$1.07+0.05 (+4.9%)
Updated Dec 7, 2023
LCTX Price
Fair Value Price
Market Cap
52 Week Low
52 Week High
Dividend Yield
Gross Margin
Operating Margin
Profit Margin
Debt to Equity
Operating Cash Flow
Next Earnings
Next Dividend

LCTX Overview

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in clinical trial for the treatment of HIV-associated facial lipoatrophy; HyStem, a biomaterial used for cell replacement and retention; and Premvia, a Hystem Hydrogel product, as well as develops bone grafting products for the orthopedic diseases and injuries. In addition, the company offers various therapeutic products for the treatment of oncology, neurological diseases and disorders, blood and vascular system diseases and disorders, and blood plasma volume expansion, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.

Zen Score

Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how LCTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

LCTX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LCTX is good value based on its book value relative to its share price (2.75x), compared to the US Biotechnology industry average (5.45x)
P/B vs Industry Valuation
LCTX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more LCTX due diligence checks available for Premium users.

Be the first to know about important LCTX news, forecast changes, insider trades & much more!


LCTX price to earnings (PE)

For valuing profitable companies with steady earnings

LCTX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
LCTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

LCTX's financial health

Profit margin

Net Income
Profit Margin
LCTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
LCTX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Debt to equity
LCTX's short-term assets ($43.48M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LCTX's short-term assets ($43.48M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LCTX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
LCTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

LCTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

LCTX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B

Lineage Cell Therapeutics Stock FAQ

What is Lineage Cell Therapeutics's quote symbol?

(NYSEMKT: LCTX) Lineage Cell Therapeutics trades on the NYSEMKT under the ticker symbol LCTX. Lineage Cell Therapeutics stock quotes can also be displayed as NYSEMKT: LCTX.

If you're new to stock investing, here's how to buy Lineage Cell Therapeutics stock.

What is the 52 week high and low for Lineage Cell Therapeutics (NYSEMKT: LCTX)?

(NYSEMKT: LCTX) Lineage Cell Therapeutics's 52-week high was $1.58, and its 52-week low was $0.93. It is currently -32.28% from its 52-week high and 15.05% from its 52-week low.

How much is Lineage Cell Therapeutics stock worth today?

(NYSEMKT: LCTX) Lineage Cell Therapeutics currently has 174,986,671 outstanding shares. With Lineage Cell Therapeutics stock trading at $1.07 per share, the total value of Lineage Cell Therapeutics stock (market capitalization) is $187.24M.

Lineage Cell Therapeutics stock was originally listed at a price of $19.00 in Dec 31, 1997. If you had invested in Lineage Cell Therapeutics stock at $19.00, your return over the last 25 years would have been -94.37%, for an annualized return of -10.87% (not including any dividends or dividend reinvestments).

How much is Lineage Cell Therapeutics's stock price per share?

(NYSEMKT: LCTX) Lineage Cell Therapeutics stock price per share is $1.07 today (as of Dec 7, 2023).

What is Lineage Cell Therapeutics's Market Cap?

(NYSEMKT: LCTX) Lineage Cell Therapeutics's market cap is $187.24M, as of Dec 8, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Lineage Cell Therapeutics's market cap is calculated by multiplying LCTX's current stock price of $1.07 by LCTX's total outstanding shares of 174,986,671.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.